13F HOLDINGS REPORT
CAXTON CORP
Quarter ended Q1 2024 · Filed May 15, 2024 · Accession 0000919574-24-003094
Total Value
$17.6M
Positions
11
Other Managers
0
Confidential Omitted
Yes
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | XERIS BIOPHARMA HOLDINGS INC | XERS | 5,113,348 | $11.3M | 64.38% |
| 2 | REZOLUTE INC | RZLT | 1,318,967 | $3.4M | 19.16% |
| 3 | SPDR S&P 500 ETF TR | SPY | 1,856 | $970,988 | 5.53% |
| 4 | BERKSHIRE HATHAWAY INC DEL | BRK-A | 1,019 | $428,308 | 2.44% |
| 5 | KYVERNA THERAPEUTICS INC | KYTX | 15,846 | $393,614 | 2.24% |
| 6 | MOLECULAR TEMPLATES INC | 608550208 | 136,866 | $306,580 | 1.75% |
| 7 | MIND MEDICINE MINDMED INC | 60255C885 | 29,065 | $273,207 | 1.56% |
| 8 | ABIVAX SA | AAVXF | 15,808 | $226,055 | 1.29% |
| 9 | LEXEO THERAPEUTICS INC | LXEO | 10,319 | $161,796 | 0.92% |
| 10 | COMPASS THERAPEUTICS INC | CMPX | 43,465 | $86,062 | 0.49% |
| 11 | ADICET BIO INC | ACET | 17,488 | $41,096 | 0.23% |